The aim of the present study is to validate the uptake of novel, positron emitting
radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim
to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed
tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with
existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The
investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging
modality for identification of HCC lesions in the liver. The investigators intend to use the
results of this preliminary study to fuel further studies in the utility of 68Ga-citrate
PET/CT for HCC treatment monitoring.